Get the Stockscreener App
26.51
1.15%
-0.3329
Xencor Inc stock is traded at $26.51, with a volume of 184.44K.
It is down -1.15% in the last 24 hours and up +24.79% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
See More
Previous Close:
$26.84
Open:
$26.69
24h Volume:
184.44K
Relative Volume:
0.33
Market Cap:
$1.87B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-12.39
EPS:
-2.14
Net Cash Flow:
$23.50M
1W Performance:
+4.86%
1M Performance:
+24.79%
6M Performance:
+10.73%
1Y Performance:
+41.12%
1-Day Range:
$26.46
$26.93
1-Week Range:
$25.24
$27.20
52-Week Range:
$15.31
$27.20
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
26.54 | 1.87B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.81 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.34 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor stock hits 52-week high at $26.89 amid robust gains - Investing.com
Baker BROS. Advisors LP Purchases 125,000 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Critical Insights From Xencor Analyst Ratings: What You Need To Know - Benzinga
Erste Asset Management GmbH Takes Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Piper Sandler upgrades Xencor stock, highlights expanding pipeline and Phase I/II data - Investing.com
Connor Clark & Lunn Investment Management Ltd. Invests $362,000 in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Victory Capital Management Inc. Trims Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Braidwell LP Takes Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Short Interest in Xencor, Inc. (NASDAQ:XNCR) Declines By 18.2% - MarketBeat
Thrivent Financial for Lutherans Raises Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Thrivent Financial for Lutherans Acquires 65,180 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Loomis Sayles & Co. L P Has $18.10 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Objective long/short (XNCR) Report - Stock Traders Daily
Xencor to Present at Two Major Healthcare Investor Conferences in December | XNCR Stock News - StockTitan
Xencor to Participate at Upcoming Investor Conferences - Business Wire
Xencor CEO Bassil Dahiyat sells $1.19 million in stock By Investing.com - Investing.com Nigeria
Xencor CEO Bassil Dahiyat sells $1.19 million in stock - Investing.com India
KBC Group NV Acquires 1,213 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor: Plamotamab NHL Data Leads To RA Program Advancement (NASDAQ:XNCR) - Seeking Alpha
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
Principal Financial Group Inc. Sells 15,251 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor Reports Q3 2024 Earnings and Program Updates - TipRanks
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade - MSN
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
(XNCR) Proactive Strategies - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Xencor Inc - GuruFocus.com
US Bancorp DE Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor CEO Dahiyat Bassil sells shares worth $80,841 - Investing.com
Xencor executive sells shares worth $1.6 million By Investing.com - Investing.com Australia
Xencor executive sells shares worth $1.6 million - Investing.com India
PRIMECAP Management Bolsters Stake in Xencor Inc - GuruFocus.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead - Investing.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Australia
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% - Yahoo Finance UK
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Creative Planning - Defense World
Xencor’s (XNCR) “Outperform” Rating Reiterated at BMO Capital Markets - Defense World
Xencor (NASDAQ:XNCR) Given New $28.00 Price Target at JPMorgan Chase & Co. - Defense World
Xencor (NASDAQ:XNCR) Given Outperform Rating at Wedbush - Defense World
Leerink Partnrs Brokers Lift Earnings Estimates for Xencor - MarketBeat
What is Wedbush’s Forecast for Xencor FY2024 Earnings? - Defense World
Leerink Partnrs Increases Earnings Estimates for Xencor - Defense World
What is Wedbush's Forecast for Xencor FY2024 Earnings? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Xencor (NASDAQ:XNCR) Receives "Outperform" Rating from BMO Capital Markets - MarketBeat
Xencor shares target raised, rating held on pipeline progress By Investing.com - Investing.com Canada
Xencor shares target raised, rating held on pipeline progress - Investing.com
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):